---
title: "Key facts: Eli Lilly Q4 2025 sales soar 43% to $19.3B; joins TrumpRx"
description: "Eli Lilly's Q4 2025 earnings revealed a 43% sales rise to $19.3 billion, surpassing forecasts. The company expects 2026 revenue of $81.5 billion and adjusted EPS of $34.25.1Eli Lilly is joining the Tr"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/275210153.md"
published_at: "2026-02-07T20:03:01.000Z"
---

# Key facts: Eli Lilly Q4 2025 sales soar 43% to $19.3B; joins TrumpRx

> Eli Lilly's Q4 2025 earnings revealed a 43% sales rise to $19.3 billion, surpassing forecasts. The company expects 2026 revenue of $81.5 billion and adjusted EPS of $34.25.1Eli Lilly is joining the TrumpRx initiative, providing discounted cash prices on around 40 drugs, allowing consumers to buy medications directly at lower prices with a TrumpRx coupon.2

-   Eli Lilly's Q4 2025 earnings revealed a 43% sales rise to $19.3 billion, surpassing forecasts. The company expects 2026 revenue of $81.5 billion and adjusted EPS of $34.25.1
-   Eli Lilly is joining the TrumpRx initiative, providing discounted cash prices on around 40 drugs, allowing consumers to buy medications directly at lower prices with a TrumpRx coupon.2

### Related Stocks

- [IHE.US - iShares US Pharma](https://longbridge.com/en/quote/IHE.US.md)
- [FBT.US - First Trust NYSE Arca Biotech Index Fd](https://longbridge.com/en/quote/FBT.US.md)
- [IBBQ.US - Invesco Nasdaq Biotechnology ETF](https://longbridge.com/en/quote/IBBQ.US.md)
- [BIB.US - Proshares Ultra Nasdaq Biotech](https://longbridge.com/en/quote/BIB.US.md)
- [VHT.US - VG Health](https://longbridge.com/en/quote/VHT.US.md)
- [ARKG.US - Ark Genomic Revolution ETF](https://longbridge.com/en/quote/ARKG.US.md)
- [ELIS.US - Direxion Daily LLY Bear 1X Shares](https://longbridge.com/en/quote/ELIS.US.md)
- [SBIO.US - ALPS Medical Breakthrough](https://longbridge.com/en/quote/SBIO.US.md)
- [IBB.US - iShares Biotechnology ETF](https://longbridge.com/en/quote/IBB.US.md)
- [ELIL.US - Direxion Daily LLY Bull 2X Shares](https://longbridge.com/en/quote/ELIL.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| China's Innovent clinches new Lilly deal for immunology, cancer drug development | China’s Innovent Biologics has secured a new deal with Eli Lilly for the development of immunology and oncology drugs, i | [Link](https://longbridge.com/en/news/275255059.md) |
| Lilly's bowel disease drug gets approval in China  | Eli Lilly has received approval from Chinese regulators for its drug mirikizumab, aimed at treating chronic inflammatory | [Link](https://longbridge.com/en/news/275554667.md) |
| Eli Lilly: Mirikizumab approved in China for treatment of moderate-to-severe Crohn's disease and ulcerative colitis - Co statement | Eli Lilly: Mirikizumab approved in China for treatment of moderate-to-severe Crohn's disease and ulcerative colitis - Co | [Link](https://longbridge.com/en/news/275551012.md) |
| Novo Nordisk Plans Wegovy Vial Launch To Counter Eli Lilly, Target Broader Obesity Market | Novo Nordisk plans to launch Wegovy in vials in the U.S. to compete with Eli Lilly in the weight-loss drug market. This  | [Link](https://longbridge.com/en/news/275794475.md) |
| Eli Lilly spokesperson: Look forward to decisive steps FDA has announced it will take, and we urge other regulators and law enforcement to do the same | Eli Lilly spokesperson: Look forward to decisive steps FDA has announced it will take, and we urge other regulators and  | [Link](https://longbridge.com/en/news/275211438.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.